Top Markets
#1 Black Phoenix Black Phoenix +831.35%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +29.79%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.50%
#4 Beam Beam +26.38%
#5 SAFEcoin SAFEcoin +20.76%
#6 Magma Finance Magma Finance +20.25%
#7 pipedog pipedog +19.56%
#8 PondCoin PondCoin +18.82%
#9 THORChain THORChain +16.58%
#10 Bless Bless +16.25%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Clasificación en acciones #6083
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Precio por acción
$153.90
Capitalización bursátil
$2.21B
Cambio (1 día)
-0.28%
Cambio (1 año)
172.63%
País
US
Comercio Palvella Therapeutics, Inc. (PVLA)

Categoría

Healthcare
Ingresos de Palvella Therapeutics, Inc. (PVLA)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Palvella Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Palvella Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH